Cargando…

Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression

BACKGROUND: The early growth response 1 (EGR1) is a central transcription factor involved in systemic sclerosis (SSc) pathogenesis. Iguratimod is a synthesized anti-rheumatic disease-modifying drug, which shows drastic inhibition to EGR1 expression in B cells. This study is aiming to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Lichong, Yin, Hanlin, Sun, Li, Zhang, Zhiliang, Jin, Yuyang, Cao, Shan, Fu, Qiong, Fan, Chaofan, Bao, Chunde, Lu, Liangjing, Zhan, Yifan, Xu, Xiaojiang, Chen, Xiaoxiang, Yan, Qingran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439582/ https://www.ncbi.nlm.nih.gov/pubmed/37596660 http://dx.doi.org/10.1186/s13075-023-03135-2

Ejemplares similares

Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer
por: Yan, Qingran, et al.
Publicado: (2023)

Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study
por: Kang, Yuening, et al.
Publicado: (2020)

Prevention of Immune Nephritis by the Small Molecular Weight Immunomodulator Iguratimod in MRL/lpr Mice
por: Yan, Qingran, et al.
Publicado: (2014)

Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis
por: Ye, Yan, et al.
Publicado: (2019)

Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study
por: Yan, Qingran, et al.
Publicado: (2023)

Iguratimod efficacy in palindromic rheumatism treatment
por: Yuan, Fangfang, et al.
Publicado: (2023)

Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study)
por: Yan, Qingran, et al.
Publicado: (2021)

Preparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma
por: Han, Jun-ping, et al.
Publicado: (2019)

Targeting miR-155 to Treat Experimental Scleroderma
por: Yan, Qingran, et al.
Publicado: (2016)

Corrigendum: Targeting miR-155 to Treat Experimental Scleroderma
por: Yan, Qingran, et al.
Publicado: (2016)

Iguratimod Inhibits the Aggressiveness of Rheumatoid Fibroblast-Like Synoviocytes
por: Lin, Jin, et al.
Publicado: (2019)

Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
por: Li, Jiangtao, et al.
Publicado: (2013)

Iguratimod Attenuates Macrophage Polarization and Antibody-Mediated Rejection After Renal Transplant by Regulating KLF4
por: Hang, Zhou, et al.
Publicado: (2022)

Iguratimod alleviates tubulo-interstitial injury in mice with lupus
por: Xue, Leixi, et al.
Publicado: (2022)

Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020)

Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome
por: Li, Qianqian, et al.
Publicado: (2022)

Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020)

Allergic Skin Rash Caused by Iguratimod: A Report of Two Cases
por: Lu, Wentian, et al.
Publicado: (2022)

Ciclesonide/iguratimod: Prolonged presence of SARS-CoV-2: case report
Publicado: (2020)

Randomised, Double-Blind, Placebo-Controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
por: Li, Yan, et al.
Publicado: (2021)

Influence of Iguratimod on Bone Metabolism in Patients with Rheumatoid Arthritis: A Meta-analysis
por: Deng, Li, et al.
Publicado: (2022)

Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology
por: Li, Jie, et al.
Publicado: (2019)

RIPK1 downregulation enhances neutrophil extracellular traps in psoriasis
por: Meng, Xinyu, et al.
Publicado: (2022)

Conflict between efficacy and economy in rheumatoid arthritis treatment: Iguratimod is found at a compromise
por: Tanaka, Masao
Publicado: (2021)

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases
por: Long, Zhiyong, et al.
Publicado: (2023)

Effects of iguratimod on inflammatory factors and apoptosis of submandibular gland epithelial cells in NOD mice
por: Wang, Shuying, et al.
Publicado: (2023)

Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
por: Ouyang, Dan, et al.
Publicado: (2022)

Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis
por: Xu, Yunzhi, et al.
Publicado: (2015)

Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature
por: Li, Xiao-li, et al.
Publicado: (2018)

Effectiveness and Safety of Iguratimod in Treating Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
por: Pu, Jincheng, et al.
Publicado: (2021)

Iguratimod in treatment of primary Sjögren’s syndrome concomitant with autoimmune hemolytic anemia: A case report
por: Zhang, Juan, et al.
Publicado: (2022)

Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis
por: Zeng, Huiqiong, et al.
Publicado: (2022)

Inverse Gottron’s papules and mechanic’s hands after a tug of war: triggered by friction and pressure?
por: Yin, Hanlin, et al.
Publicado: (2021)

Puffy fingers and abnormal nail fold capillaries
por: Yin, Hanlin, et al.
Publicado: (2023)

The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
por: Inoue, Asuka, et al.
Publicado: (2020)

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
por: Nozaki, Yuji
Publicado: (2021)

Iguratimod Ameliorates the Severity of Secondary Progressive Multiple Sclerosis in Model Mice by Directly Inhibiting IL-6 Production and Th17 Cell Migration via Mitigation of Glial Inflammation
por: Nagata, Satoshi, et al.
Publicado: (2023)

Iguratimod promotes transformation of mononuclear macrophages in elderly patients with rheumatoid arthritis by nuclear factor-κB pathway
por: Liu, Sha, et al.
Publicado: (2021)

Clinical Efficacy of Methotrexate Combined with Iguratimod on Patients with Rheumatoid Arthritis and Its Influence on the Expression Levels of HOTAIR in Serum
por: Tan, Jingya, et al.
Publicado: (2021)

Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs
por: Hu, Chao-Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lieasqmtp7ft6sf8i535aqgiau